ShareValue scores for 1349.HK: Valuation 51, Quality 61, Growth 27, Health 72.
1349.HKHKEX
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
HK$2.37
(-1.25%)
1349.HKHKEX
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Verdicts
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
Rating
Trap Risk
Return
Company Details
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.